Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mechanism of action of alefacept · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Mechanism of action of alefacept | DRUG | - |
Inclusion Criteria * Alefacept is indicated for the treatment of adult patients (18 years or older) with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. Patients must have at least one plaque of least 2.5 cm in diameter (for biopsies). Exclusion...
Alefacept is an investigational drug being studied for the treatment of psoriasis. It is currently in Phase 2 clinical development. The drug is being evaluated in patients with psoriasis to understand its mechanism of action. It is not yet approved by the FDA and remains in clinical trials.
Alefacept is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical research on this drug for the treatment of psoriasis. Biogen is responsible for the ongoing development and clinical trials of alefacept.
Alefacept is currently in Phase 2 clinical development. It has completed one clinical trial, which was a Phase 2 study. The drug is still investigational and has not been approved by regulatory authorities. Further clinical development may be needed before it can be considered for approval.
Alefacept has been studied in one completed clinical trial with the identifier NCT00150982. This Phase 2 trial was titled "Alefacept Mechanism of Action in Psoriasis" and enrolled 9 participants in the United States. The study was uncontrolled and not randomized or double-blinded, and it included biomarker selection.
Alefacept is a distinct drug candidate being developed by Biogen Inc. for psoriasis. No alternative names for this drug have been established in the available clinical trial information. It is being studied under its own name in the context of its Phase 2 clinical trial.